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AbstrAct
Objectives To determine the prevalence of potentially 
inappropriate prescribing (PIP) in a cohort of community-
dwelling middle-aged people and assess the relationship 
between PIP and emergency department (ED) visits, 
general practitioner (GP) visits and quality of life (QoL).
Design Prospective cohort study.
setting The Irish Longitudinal Study on Ageing (TILDA), a 
nationally representative cohort study of ageing.
Participants Individuals aged 45–64 years recruited to 
TILDA who were eligible for the means-tested General 
Medical Services scheme and followed up after 2 years.
Exposure PIP was determined in the 12 months 
preceding baseline and follow-up TILDA data collection 
by applying the PRescribing Optimally in Middle-aged 
People’s Treatments (PROMPT) criteria to participants’ 
medication dispensing data.
Outcome measures At follow-up, the reported rates of 
ED and GP visits over 12 months (primary outcome) and 
the CASP-R12 (Control Autonomy Self-realisation Pleasure) 
measure of QoL (secondary outcome).
Analysis Multivariate negative binomial (rates) and linear 
regression (CASP-R12) models controlling for potential 
confounders.
results At 2-year follow-up (n=808), PIP was detected in 
42.9% by the PROMPT criteria. An ED visit was reported by 
18.7% and 94.4% visited a GP (median 4 visits, IQR 2–6). 
Exposure to ≥2 PROMPT criteria was associated with higher 
rates of healthcare utilisation and lower QoL in unadjusted 
regression. However, in multivariate analysis, the associations 
between PIP and rates of ED visits (adjusted incidence rate 
ratio (IRR) 0.92, 95% CI 0.53 to 1.58), and GP visits (IRR 
1.06, 95% CI 0.87 to 1.28), and CASP-R12 score (adjusted β 
coefficient 0.35, 95% CI −0.93 to 1.64) were not statistically 
significant. Numbers of medicines and comorbidities were 
associated with higher healthcare utilisation.
conclusions Although PIP was prevalent in this study 
population, there was no evidence of a relationship with ED 
and GP visits and QoL. Further research should evaluate 
whether the PROMPT criteria are related to these and other 
adverse outcomes in the general middle-aged population.
IntrODuctIOn
Potentially inappropriate prescribing (PIP) 
includes the use of medicines such that the 
risks outweigh the benefits or where a safer 
alternative exists.1 2 Most research on PIP has 
focused on older patients (aged ≥65 years), as 
they tend to be at greater risk of adverse drug 
events owing to changes in drug pharmaco-
kinetics and pharmacodynamics that occur 
with ageing and increased likelihood of being 
on multiple medicines or having multiple 
conditions.1 Although chronological age is 
used as a marker for these factors, multimor-
bidity and polypharmacy are also prevalent in 
individuals in middle age (usually defined as 
between 45 and 64 years), particularly among 
socioeconomically deprived groups.3 4 Age-re-
lated physiological changes also do not occur 
at a single time point; rather, they develop on 
a continuum, with renal blood flow declining 
by 1% per year from the age of 50 years, for 
example.5 6 To date, there has been a paucity of 
research on PIP in middle-aged adults despite 
adverse drug events being more strongly asso-
ciated with the numbers of medicines and diag-
noses a person has than chronological age.7 8
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Research
strengths and limitations of this study
 ► This is the first study to assess the relationship 
between the PRescribing Optimally in Middle-aged 
People’s Treatments criteria and health outcomes in 
a middle-aged population.
 ► Detailed information on dispensed medicines from 
an administrative pharmacy claims database was 
analysed.
 ► Participants in this study are not representative of 
the general middle-aged population due to their 
lower socioeconomic status.
 ► Exposure to potentially inappropriate prescribing 
(PIP) was measured over a fixed 12-month period 
prior to outcome measurement, so only sustained 
adverse effects of PIP would have been detected.
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have recently been developed as explicit indicators of PIP 
in middle-aged adults, specifying circumstances in which 
prescribing may be inappropriate.9 The risk of adverse 
effects from prescribing considered to be potentially inap-
propriate is often assumed to be lower in younger people 
than in individuals over 65 years,8 because superior baseline 
levels of physiological functioning generally mean higher 
drug concentrations are required in younger people to 
reach an adverse event-threshold effect.10 However, indi-
vidual patient characteristics, such as comorbidities and the 
number of medicines being taken, may be more important 
than actual age in affecting drug response.6 Risk of adverse 
events for medicines included in PIP criteria can be similar 
in older and middle-aged groups after controlling for 
patient characteristics, as has been found, for example, with 
non-steroidal anti-inflammatory drugs (NSAIDs).11
The PROMPT criteria are a relatively new measure of 
PIP and although the prevalence has been evaluated, any 
relationship with important outcomes for patients has yet 
to be investigated.2 12 It is necessary to determine if expo-
sure to the PROMPT criteria has an impact on middle-
aged patients’ outcomes, independent of any effect of 
multimorbidity and polypharmacy, to justify the use of 
these criteria as a process measure of prescribing quality 
or as part of any intervention to reduce PIP.
The aims of this study were: (1) to determine the prev-
alence of PIP using the PROMPT criteria in a cohort of 
community-dwelling middle-aged people, (2) to deter-
mine factors associated with change in prevalence over 
time in this cohort, and (3) to assess the prospective rela-
tionship between PIP and the outcomes of healthcare 
utilisation and quality of life (QoL).
MEthODs
study design and setting
This prospective cohort study included participants from 
The Irish Longitudinal Study on Ageing (TILDA), which 
is a nationally representative cohort study examining the 
health, economic and social circumstances of middle-
aged and older people living in the community.13 TILDA 
recruited approximately 8000 people in Ireland, based on 
a random selection process using a national geodirectory 
of residential addresses. While the target population was 
community-dwellers aged 50 years or over, participants’ 
spouses and partners of any age were also invited to take part. 
Participants were asked to consent to use of their adminis-
trative pharmacy claims data from the Health Service Exec-
utive Primary Care Reimbursement Service (HSE-PCRS). 
Participants were included in the present study if they (1) 
were aged 45 years or older at baseline (Wave 1) TILDA 
interview and 64 years or less at follow-up (Wave 2) inter-
view, (2) were eligible for the General Medical Services 
(GMS) scheme, and (3) provided a GMS identifier which 
was successfully linked to their pharmacy claims data (see 
figure 1). The GMS scheme is public health cover in Ireland 
providing free health services, including most prescribed 
medicines, to those who are eligible, although a small 
monthly copayment per prescription item was introduced 
in 2010. Eligibility for the GMS scheme is based on means 
testing (covering approximately 33% of the 45–64 years 
age group in 2012) and so this cohort is considered more 
socioeconomically deprived than the general middle-aged 
population.14 The STROBE (Strengthening the Reporting 
of Observational Studies in Epidemiology) standardised 
reporting guidelines for cohort studies have been followed 
in the reporting of this research.15
Data collection
TILDA data collection is conducted in waves every 2 years 
incorporating a face-to-face interview, self-completion ques-
tionnaire and a health assessment.13 Baseline data collec-
tion was carried out from October 2009 to February 2011 
and participants were followed up after approximately 
2 years between February 2012 and March 2013. Trained 
interviewers visited participants in their own homes where 
they conducted a computer-assisted personal interview 
(CAPI), which ensured consistent ordering and wording of 
questions, and full CAPI documentation is available on the 
TILDA website. Details of prescribed medicines that were 
dispensed were extracted from the HSE-PCRS pharmacy 
claims database for each participant in the present study 
from 15 months before the date of their TILDA baseline 
interview up to their follow-up interview and all identifiable 
information was removed after extraction. Ethical approval 
for TILDA was provided by the Faculty of Health Sciences 
Ethics Committee, Trinity College Dublin, and included 
provision for the secondary analysis of collected data and 
provision for linkage to participant’s GMS dispensing 
information.
Prevalence of PIP
Application of PROMPT criteria
The prevalence of PIP using the PROMPT criteria was 
determined in this cohort during two time intervals: 
(1) the 12 months preceding the date of each partici-
pant’s baseline TILDA interview and (2) the 12 months 
preceding their follow-up interview. PIP was assessed by 
applying the PROMPT criteria to participants’ medi-
cine dispensing data and information from TILDA on 
diagnoses and other characteristics. All 22 PROMPT 
criteria were applicable to the data available and each 
was assessed based on the same assumptions as in the 
previous paper applying the PROMPT criteria14; details 
of these and how various types of criteria were applied to 
the data are both provided in online supplementary box 
S1. Data were available for all participants to assess PIP 
prevalence during both time intervals. For criteria depen-
dent on duration of use greater than 1 month, a longer 
period of time was analysed by including a lead-in period 
to allow for 12 months of potential exposure.
Statistical analysis
The prevalence of PIP for each time period was calculated 
as the proportion of the cohort with any PROMPT crite-
rion, and this was also assessed by the number of PROMPT 
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Figure 1 Flow diagram of study participants from The Irish Longitudinal Study on Ageing (TILDA) cohort aged 45–64 years. 
ED, emergency department; GP, general practitioner; GMS, General Medical Services.
criteria per individual (considering any number of dupli-
cated drug classes as one PIP criterion). The proportion 
of the study cohort with each individual criterion was also 
determined. The absolute change in prevalence between 
these two periods (with 95% confidence intervals (CI)) 
was calculated and McNemar’s test for paired groups was 
used to assess if the overall prevalence and prevalence per 
criterion had changed significantly over time.
Generalised estimating equations (GEE) with exchange-
able correlations were used to investigate the determinants 
of population-averaged change in PIP prevalence between 
the time periods.16First, unadjusted GEE analysis was used 
to assess the odds of having any PIP at follow-up compared 
with baseline, and then multivariate analysis was performed 
which adjusted for factors shown previously to be associated 
with PIP (see Table S1), including age, sex and number 
of regular medicines,14 as well as reported number of 
doctor-diagnosed chronic conditions,17 and level of educa-
tional attainment as an indicator of socioeconomic status 
(SES).18 19 Unadjusted and adjusted odds ratios (OR) with 
95% CI are presented.
Association with patient outcomes
Outcomes
The primary outcome was healthcare utilisation, specif-
ically rates of emergency department (ED) visits and 
general practitioner (GP) visits. This was based on self-re-
port and TILDA participants were asked during inter-
view to recall how many times in the last 12 months they 
visited a hospital ED as a patient, and about how often 
they visited their GP.
The secondary outcome was QoL, which was assessed 
in the self-completion questionnaire which TILDA partic-
ipants complete and return postinterview. The CASP-19 
(Control Autonomy Self-realisation Pleasure) was the 
included measure, which was developed for use in studies 
of ageing and is applicable to older individuals and 
people in middle age.20 Participants rate how often each 
statement in the measure describes how they feel, giving 
a possible range from 0 (worst quality of life) to 57 (best 
quality of life). A revised 12-item version of CASP (CASP-
R12), which has been demonstrated to have improved 
psychometric validity, was used as the secondary outcome 
measure in this analysis.21
Covariates
The exposure of interest was PIP, specifically the number 
of PROMPT criteria that a participant was exposed to in 
the 12 months preceding outcome measurement. Partic-
ipant demographics such as age, sex and level of educa-
tional attainment were included as potential confounders. 
As patients with polypharmacy and/or multimorbidity are 
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Table 1 Descriptive statistics for participants at baseline (Wave 1) and follow-up (Wave 2)
Characteristic Baseline (n=921) Follow-up (n=808)
Age (year, mean (SD)) 56.11 (4.13) 58.01 (4.06)
Female sex (n (%)) 560 (60.8) 486 (60.2)
Number of regular medicines (median (IQR)) 3 (0–5) 4 (1–6)
Number of reported conditions (n (%))
  0 183 (19.9) 99 (12.3)
  1 260 (28.2) 190 (23.5)
  2 240 (26.1) 198 (24.5)
  3+ 238 (25.8) 321 (39.7)
Level of education attainment (n (%))
  Primary 320 (34.7) 265 (32.8)
  Secondary 443 (48.1) 399 (49.4)
  Tertiary 158 (17.2) 144 (17.8)
Depressive symptoms* (n (%))
  None 517 (57.1) 492 (61.7)
  Subclinical 200 (22.1) 157 (19.7)
  Clinical 189 (20.9) 148 (18.6)
*Missing for 15 participants (1.6%) at baseline, and 11 (1.4%) at follow-up.
more likely to be exposed to PIP, number of regular medi-
cines and number of doctor-diagnosed chronic conditions 
were also included.17 22 Covariates specific to each outcome 
were also considered, such as the number of ED/GP visits 
reported by the participants in 12 months preceding base-
line interview for healthcare utilisation. For QoL, baseline 
CASP-R12 score and level of depressive symptoms screened 
using the Centre for Epidemiological Studies Depres-
sion scale (CES-D) at follow-up were considered. Further 
description of each covariate is included in online supple-
mentary table S1.
Statistical analysis
The relationship between PIP and healthcare utilisation 
was assessed by fitting separate negative binomial regres-
sion models for the reported numbers of (1) ED visits in 
the 12 months preceding follow-up interview and (2) GP 
visits in the same period. PIP exposure was included as a 
variable for number of criteria, coded as 0 (reference), 1 
and ≥2 PROMPT criteria to investigate a potential dose–
response relationship. Univariate analysis was conducted, 
followed by multivariate analysis adjusting for potential 
confounders. For covariates that could vary over time, the 
value at the latest time point prior to outcome measure-
ment was used. Results of these analyses are presented as 
incidence rate ratios (IRR) with 95% CI. A similar analyt-
ical approach was used for the secondary outcome of QoL 
using participants’ CASP-R12 score measured at follow-up 
(possible range 0–36) as the continuous outcome vari-
able. Univariate and multivariate linear regression analyses 
were conducted and results are presented as β regression 
coefficients with 95% CI. Multicollinearity in the models 
was assessed using variance inflation factors. Two-sided 
statistical significance was assumed at p<0.05. Analyses were 
performed using Stata V.13 (Stata Corporation, College 
Station, Texas, USA).
Sensitivity analysis
The impact of time-dependent confounding (by number of 
regular medicines or chronic conditions for example) was 
investigated using marginal structural models (MSMs).23 24 
Two types of analytical weight were calculated for each partic-
ipant. The first type was stabilised inverse probability 
weights, the inverse of the probability of having their PIP 
exposure conditional on past PIP exposure and covariate 
history (both baseline and time-varying). The second type 
was censoring weights, the probability of remaining uncen-
sored (ie, being followed up at Wave 2) given past PIP 
exposure and covariate history. Weighted regression anal-
yses (ie, MSMs) were performed for each outcome using 
the product of these weights, including a binary PROMPT 
exposure variable and baseline covariates only.
rEsults
Participants
At baseline, 921 TILDA participants aged 45–64 years were 
included and of these, 808 (87.8%) completed follow-up 
interview after 2 years (figure 1). Those followed up were 
predominantly female (60.2%), had a mean age of 58.0 
years (SD 4.0), a median of four regular medicines (IQR 
1–6) and two reported doctor-diagnosed chronic condi-
tions (IQR 1–3) (table 1).
Prevalence of PIP and change over time
Overall, 361 participants had at least one PROMPT 
criteria in the 12 months prebaseline interview (39.2%). 
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Considering number of PROMPT criteria, 21.6% of 
participants had one, 10.3% had two and 7.3% had three 
or more criteria in this time period (table 2). In the 12 
months preceding follow-up interview, the prevalence 
had increased significantly to 42.9%, with the breakdown 
by number of criteria for one, two and three or more 
being 22.1%, 11.9% and 8.9%, respectively.
As shown in table 2, the most prevalent PIP criteria at 
baseline were long-term PPIs at higher than maintenance 
dose (prescribed to 14.8% of participants), strong opioids 
without a laxative (13.9%), long-term use of benzodiaze-
pines (7.6%), of non-benzodiazepine or Z-drug hypnotics 
(7.6%) and of NSAIDs (6.2%). Of these, statistically signif-
icant increases in prevalence over the 2-year period were 
observed for long-term PPIs above maintenance dose 
(to 19.2%, McNemar’s test p<0.001), long-term use of 
non-benzodiazepine hypnotics (to 9.2%, p<0.05) and of 
NSAIDs (to 8.3%, p<0.05), as well as for duplicate opioid 
prescribing (from 0.8% to 2.3%, p<0.01). The rank order 
of the most prevalent criteria did not change between 
the two time periods. Although most criteria increased in 
prevalence, a number did decrease, although not signifi-
cantly, such as use of NSAIDs without gastroprotection 
with low-dose aspirin (from 4.3% to 2.2%) or with selec-
tive serotonin reuptake inhibitors (from 2.8% to 1.6%), 
and duplicate benzodiazepines (from 2.2% to 1.3%) or 
NSAIDs (from 1.0% to 0.5%).
Analysis of factors associated with change in prevalence 
as shown in table 3 found that while the overall preva-
lence increased significantly at follow-up (unadjusted OR 
1.08, 95% CI 1.01 to 1.15, for follow-up compared with 
baseline), this was no longer significant after adjusting for 
patient factors (adjusted OR 0.93, 95% CI 0.85 to 1.02). 
Numbers of medicines and diagnosed conditions, and 
female sex were all significantly associated with a higher 
odds of PIP in the multivariate analysis, and tertiary level 
education (relative to primary) was associated with lower 
odds of PIP (table 3).
Association with patient outcomes
At follow-up interview, 18.7% of the cohort reported 
visiting an ED in the previous 12 months, and of these, 
13.1% of participants reported one ED visit, 2.9% reported 
two and 2.7% reported three or more. During the same 
time frame, 94.4% of participants reported visiting a GP 
(median four visits, IQR 2–6).
In univariate negative binomial regression, having two 
or more PROMPT criteria was associated with an increased 
rate of ED visits (unadjusted IRR 1.98, 95% CI 1.27 to 
3.08) relative to having no criteria but in the multivariate 
model adjusting for confounders (table 4), this associa-
tion was no longer significant (adjusted IRR 0.92, 95% CI 
0.53 to 1.58). Increasing age and tertiary education (rela-
tive to primary) were significantly associated with a lower 
rate of ED visits, while number of regular medicines was 
associated with an increased ED visit rate.
Unadjusted analysis of GP visits showed an apparent 
dose–response relationship, with an increased rate 
associated with having one PROMPT criterion (unad-
justed IRR 1.35, 95% CI 1.17 to 1.56) or two or more 
criteria (1.89, 95% CI 1.62 to 2.21) (table 4). However, 
these associations were not significant after controlling 
for confounders in multivariate analysis. Number of 
regular medicines, having three or more reported condi-
tions (relative to none) and number of GP visits at base-
line were all significantly associated with a higher rate of 
GP visits at follow-up in multivariate analysis.
CASP-R12 scores at follow-up ranged from 6 to 36 and 
the mean score was 24.8 (SD 5.8). The distribution was 
approximately normal and in model checking, none of 
the assumptions of linear regression were violated. Expo-
sure to PIP was associated with a reduction in CASP-R12 
QoL score in univariate analysis compared with those with 
no PIP (table 4), regardless of whether participants had 
one PROMPT criterion (unadjusted β coefficient −1.70, 
95% CI −2.97 to –0.44) or two or more criteria (−2.13, 
95% CI −3.45 to –0.80). This two unit reduction in CASP-
R12 score is equivalent to answering two positively worded 
statements ‘Rarely’ instead of ‘Sometimes’, for example. 
After controlling for confounders, there was no evidence 
of a significant reduction in QoL associated with any PIP 
exposure. Female sex, increasing age and higher baseline 
CASP-R12 score were significantly associated with higher 
follow-up CASP-R12 score, while presence of depressive 
symptoms (both subclinical and clinical) was associated 
with lower QoL.
In sensitivity analysis using MSMs (see online supple-
mentary table S2), although changes occurred in the 
point estimates of adjusted IRR for ED visits (from 0.95 
to 0.77) and adjusted β coefficient for CASP-R12 score 
(from −0.26 to −0.07), associations remained non-signif-
icant and so adjusting for time-varying confounding did 
not significantly alter the findings.
DIscussIOn
Principal findings
The prevalence of PIP in these middle-aged TILDA 
participants was high at 39% in the 12 months preceding 
baseline interview and this had increased significantly to 
43% at follow-up after 2 years. The increase in odds of 
having PIP at follow-up compared with baseline was not 
statistically significant once participant characteristics, 
such as number of medicines and chronic conditions, 
were accounted for. Although exposure to the PROMPT 
criteria was associated with outcomes in univariate anal-
ysis, no significant relationship between PIP and rates 
of ED and GP visits or CASP-R12 score was found once 
other factors were controlled for. The number of regular 
medicines was independently associated with higher rates 
of both ED and GP visits, while having three of more 
chronic conditions was associated with an increased rate 
of GP visits.
Findings in the context of previous research
PIP in middle-aged groups has been under-investigated; 
however, previous studies evaluating other forms of 
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Table 2 Number and percentage of participants with each PRescribing Optimally in Middle-aged People’s Treatments 
(PROMPT) criterion and change in percentage prevalence between baseline and 2-year follow-up
PROMPT criterion
Baseline
n (%)
Follow-up
n (%)
Change in % 
prevalence 
(95% CI)†
Gastrointestinal system
  Other than for opioid-induced constipation, stimulant laxatives (eg, 
bisacodyl, senna) should not be prescribed as first-line treatment in 
constipation for greater than 4 weeks
0 (0.0) 0 (0.0) 0.0 (−0.1, 0.1)
  Proton pump inhibitors (PPIs) should not be prescribed at doses above the 
recommended maintenance dosage for greater than 8 weeks
136 (14.8) 177 (19.2) 4.5 (2.1, 6.8)***‡
  Esomeprazole or omeprazole should not be used in combination with 
clopidogrel
11 (1.2) 7 (0.8) −0.4 (−1.2, 0.3)
Cardiovascular system
  The use of alpha-adrenoceptor blocking drugs (eg, doxazosin, prazosin) as 
monotherapy for hypertension should be avoided
2 (0.2) 2 (0.2) 0.0 (−0.4, 0.4)
  Aspirin doses should not exceed 150 mg/day for antiplatelet therapy 5 (0.5) 5 (0.5) 0.0 (−0.4, 0.4)
  Cardioselective calcium-channel blockers (eg, verapamil, diltiazem) should 
not be used in combination with beta-adrenoceptor blocking drugs
4 (0.4) 4 (0.4) 0.0 (−0.4, 0.4)
  The use of oral short-acting dipyridamole should not be used as 
monotherapy in antiplatelet treatment
0 (0.0) 0 (0.0) 0.0 (−0.1, 0.1)
Respiratory system
  First-generation antihistamines (eg, chlorphenamine, promethazine) should 
not be used as first-line agents for greater than 7 days.
8 (0.9) 5 (0.5) −0.3 (−1.1, 0.5)
  A concomitant bisphosphonate should be prescribed if oral corticosteroids 
are used long term (greater than 3 months)
14 (1.5) 14 (1.5) 0.0 (−1.1, 1.1)
  Theophylline should not be used as monotherapy for asthma or COPD 1 (0.1) 1 (0.1) 0.0 (−0.4, 0.4)
  Mucolytic agents (eg, carbocisteine, mecysteine) should not be used 
routinely in stable COPD
1 (0.1) 6 (0.7) 0.5 (0.0, 1.1)
Central nervous system
  Selective serotonin reuptake inhibitors (SSRIs) should not be used in 
combination with venlafaxine
1 (0.1) 0 (0.0) −0.1 (−0.4, 0.2)
  Tricyclic antidepressants (TCAs) should not be used as first-line in treatment 
of depression
0 (0.0) 0 (0.0) 0.0 (−0.1, 0.1)
  Benzodiazepines should not be used long term (greater than 4 weeks) 70 (7.6) 76 (8.3) 0.6 (−0.9, 2.2)‡
  Non-benzodiazepine hypnotics (zolpidem, zaleplon, zopiclone) should not be 
used long term (greater than 4 weeks)
70 (7.6) 85 (9.2) 1.6 (0.0, 3.3)*‡
  Carbamazepine should not be used in combination with clarithromycin or 
erythromycin
3 (0.3) 1 (0.1) −0.2 (−0.8, 0.3)
  Strong opioids (eg, buprenorphine, diamorphine, fentanyl, morphine, 
oxycodone) should not be prescribed without the coprescribing of at least 
osmotic or stimulant laxative (same month)
128 (13.9) 131 (14.2) 0.3 (−2.4, 3.0)‡
Infections
  Nitrofurantoin should not be prescribed for greater than 7 days for the 
management of uncomplicated lower urinary tract infections
2 (0.2) 8 (0.9) 0.7 (−0.1, 1.4)
Endocrine system
  In relation to the management of diabetes, the use of oral long-acting 
sulfonylureas (glibenclamide) should be avoided
0 (0.0) 0 (0.0) 0.0 (−0.1, 0.1)
Musculoskeletal system
  Non-steroidal anti-inflammatory drugs (NSAIDs) should not be used long 
term (greater than 3 months)
57 (6.2) 76 (8.3) 2.1 (0.3, 3.8)*‡
  Unless Gl protection is provided with PPI/H2-receptor antagonist, NSAIDs 
should not be used in combination with low-dose aspirin
40 (4.3) 20 (2.2) −2.2 (−2.2, 0.7)‡
Continued
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PROMPT criterion
Baseline
n (%)
Follow-up
n (%)
Change in % 
prevalence 
(95% CI)†
  Unless Gl protection is provided with PPI/H2-receptor antagonist, NSAIDs 
should not be used in combination with SSRIs
26 (2.8) 15 (1.6) −1.2 (−1.0, 1.7)‡
Duplication of drug classes
  Non-benzodiazepine (Z drug) hypnotics 0 (0.0) 1 (0.1) 0.1 (−0.2, 0.4)
  Benzodiazepines 20 (2.2) 12 (1.3) −0.9 (−1.8, 0.0)
  Opioids 7 (0.8) 21 (2.3) 1.5 (0.3, 2.7)**‡
  Loop diuretics 0 (0.0) 0 (0.0) 0.0 (−0.1, 0.1)
  NSAIDs 9 (1.0) 5 (0.5) −0.4 (−1.3, 0.5)
  ACE inhibitors 0 (0.0) 0 (0.0) 0.0 (−0.1, 0.1)
  Angiotensin II receptor blockers 2 (0.2) 0 (0.0) −0.2 (−0.6, 0.2)
  SSRI 0 (0.0) 0 (0.0) 0.0 (−0.1, 0.1)
  Tricyclic antidepressants 0 (0.0) 0 (0.0) 0.0 (−0.1, 0.1)
  Calcium channel blockers 2 (0.2) 1 (0.1) −0.1 (−0.4, 0.2)
  Beta blockers 1 (0.1) 1 (0.1) 0.0 (−0.4, 0.4)
  Statins 0 (0.0) 1 (0.1) 0.1 (−0.2, 0.4)
  Thiazide diuretics 0 (0.0) 0 (0.0) 0.0 (−0.1, 0.1)
Any above duplicate drug class 40 (4.3) 40 (4.3) 0.0 (−1.7, 1.7)
Any of above PROMPT criteria 361 (39.2) 395 (42.9) 3.7 (0.4, 6.9)*‡
Number of PROMPT criteria
  1 199 (21.6) 211 (22.9) –
  2 95 (10.3) 102 (11.1) –
  3 44 (4.8) 52 (5.7) –
  4 16 (1.7) 21 (2.3) –
  5 7 (0.8) 8 (0.9) –
  6 0 (0.0) 1 (0.1) –
†Change in prevalence may not sum to exact difference in reported baseline and follow-up prevalence due to rounding.
***p value <0.001; ** p value <0.01; * p value <0.05.
‡Significant McNemar’s test (p<0.05) calculated using non-exact p value if >20 individuals changed exposure status between time periods (ie, 
had criterion during one time period only).
ACE, angiotensin converting enzyme; COPD, chronic obstructive pulmonary disease; H2, histamine-2 receptor.
Table 2 Continued 
suboptimal prescribing have shown a similar risk of drug–
drug interactions and high-risk prescribing across middle 
and older age groups after controlling for patient factors 
such as numbers of medicines and morbidity.4 25
No studies have evaluated the effect of PIP specifically 
on middle-aged people previously. There is evidence that 
PIP in older age is associated with adverse outcomes for 
patients,26 including from older participants of TILDA 
where similar analysis to the present study demonstrated 
a relationship between PIP criteria from the Screening 
Tool for Older Persons’ Prescriptions and healthcare use 
among participants aged ≥65 years.27 Prevalent PROMPT 
criteria here related to drug classes which are also 
commonly involved in PIP in older populations, including 
PPIs, NSAIDs and benzodiazepines. Some studies have 
reported a similar risk of adverse drug events resulting 
from these medicines in younger and older patients after 
adjustment for patient characteristics, such as gastrointes-
tinal adverse events in trials of NSAIDs,11 and mortality 
risk among sedative hypnotic users.28
The relationship between age and harm from medi-
cines has been described as ambiguous.6 Reporting 
age-specific rates of adverse drug events (ADEs) often 
indicates a plateau following childhood and a sharp rise 
in older age groups29; however, previous studies have 
indicated that this may be accounted for by increasing 
volumes of medicines consumed or patients’ comor-
bidities.8 30 31 This supports the suggestion that an indi-
vidual’s physiological and clinical characteristics are 
more important than age in predicting adverse effects 
of drugs.6 However, evidence is equivocal,32 and differ-
ences between studies may be explained by classification 
of ADEs, for instance, there may be differences in seri-
ousness of ADEs or preventability across age groups33 34 
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Table 3 Factors associated with having any PRescribing Optimally in Middle-aged People’s Treatments (PROMPT) criteria in 
population-averaged generalised estimating equations models
Prevalence of any PROMPT criteria (n=919*)
Unadjusted OR (95% CI) Adjusted OR (95% CI)
Follow-up (vs baseline) 1.08 (1.01 to 1.15)† 0.93 (0.85 to 1.02)
Age (years) 1.05 (1.02 to 1.08)† 1.02 (0.99 to 1.05)
Female (vs male) 1.37 (1.08 to 1.74)† 1.44 (1.12 to 1.85)†
Number of regular medicines‡ 1.33 (1.28 to 1.40)† 1.30 (1.24 to 1.37)†
Number of chronic conditions‡ 1.46 (1.35 to 1.58)† 1.12 (1.01 to 1.23)†
Level of education (vs primary)
  Secondary 0.85 (0.66 to 1.09) 0.91 (0.69 to 1.19)
  Tertiary 0.68 (0.49 to 0.96)† 0.65 (0.45 to 0.94)†
*Self-reported number of medicines was missing at both time points for two(0.2%) participants who were excluded from this analysis.
†z score p<0.05.
‡Continuous variables with OR for each one unit increase in the number of regular medicines/chronic conditions.
or the types of ADEs and causative drug classes may also 
differ by age group.35
strengths and limitations
This appears to be the first study to assess the prospec-
tive relationship between PIP in middle-aged people and 
adverse outcomes for patients. This large longitudinal 
study which included methods to account for time-varying 
covariates allowed for improved confounding control to 
reduce potential bias. A further strength is that all 22 
PROMPT criteria were applied to determine exposure to 
PIP. Dispensing data was employed, which is likely more 
reliable than self-reported medicines use.36 However this 
required an assumption that dispensed drugs were actu-
ally taken by patients, and information on non-prescrip-
tion medicines use was lacking which may have affected 
the reliability of criteria where over-the-counter treat-
ment is available.
A limitation of this study was that ED and GP visits were 
based solely on participant recall over a 12-month period, 
and no validation against administrative records was 
possible. While there is the potential for under-reporting 
due to long recall time period,37 self-reported healthcare 
utilisation is valid across socioeconomic groups,38 and 
hospital ED visits are often recalled with more than 90% 
accuracy.39 Although the analytical approach was the same 
as in a previous study of older participants in TILDA, the 
present analysis may have been underpowered to detect 
an effect on healthcare use, given lower GP and ED visit 
rates among middle-aged people. Similarly, the effect of 
PIP on QoL observed in older people was modest,27 and 
may not have been detectable in a middle-aged cohort of 
this size. However, this study did have sufficient power to 
detect significant associations of number of regular medi-
cines, number of conditions and level of education with 
healthcare utilisation. A fixed 12-month exposure period 
was used prior to outcome measurement, which in the 
case of healthcare use was also over a fixed period of 12 
months, so any effect of PIP would have to be sustained 
beyond the exposure period in order to be detected. The 
outcomes investigated here may not be sensitive to the 
effect of PROMPT criteria as, for example, the CASP-R12 
is a measure of QoL rather than health-related QoL and 
so may not reflect health status changes. For both ED and 
GP visits, the reason for encounter was not known and so, 
for example, GP visits involving a full assessment and visits 
to collect a prescription could not be distinguished.
As participants of this study had to be eligible for the 
GMS scheme, this introduces a bias as socioeconomically 
deprived individuals are more likely to have multimorbidity 
and PIP,3 14 and therefore the prevalence of PIP is likely to 
be an overestimate of prevalence in the general popula-
tion. Although the greater level of exposure provides more 
power to detect an effect, a limitation is that this study could 
not evaluate if the relationship between PIP exposure and 
outcomes differs across levels of SES.
Practice and policy implications
It is possible that PIP may cause adverse effects in middle-
aged people but that these may not be serious enough 
to result in seeking healthcare or a sustained effect on 
QoL. Middle-aged people are likely to have superior phys-
iological reserve and so be more capable of sustaining the 
adverse effects of such prescribing than older individ-
uals.10 For example, lack of physiological changes to the 
gastric lining may offer natural resistance to the ulcero-
genic effects of long-term NSAIDs.40 41 Less postural hypo-
tension and improved balance may protect against falls 
due to benzodiazepines and lower prevalence of osteopo-
rosis reduces the chance of fracture.42
Whether intervening to reduce PIP in middle-aged 
patients would improve patient outcomes such as health-
care use and QoL remains to be seen. Further research 
should be conducted to provide more evidence on 
whether PIP in this age group is associated with adverse 
outcomes. Other end points such as medication-related 
hospital admissions, ADEs and health-related QoL should 
be evaluated as ED visits, GP visits and QoL may not be 
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sensitive to the effects of PIP in this age group. If inter-
ventions are being introduced to optimise medicines in 
older patients, because PROMPT includes similar indica-
tors to other PIP criteria lists, there may be economies of 
scale to also apply these interventions to the middle-aged 
group, if using a computer decision support system, for 
example. Most individual PROMPT criteria had a prev-
alence of less than 2% in this study, and so researchers 
and practitioners using this tool in the future should be 
cognisant of this and could consider focusing on a subset 
of high prevalence or high-risk criteria.
It is also important to consider that while a PIP drug 
may not have an adverse effect on patients in middle age, 
once a medicine is initiated, it can often persist into older 
age when the likelihood of harm may increase.43 Discon-
tinuing an inappropriate medicine may be more feasible 
after a shorter period of use, as is the case with benzodiaz-
epines due to dependence.44 Similarly, withdrawal effects 
can be worse after prolonged use and the impact of these 
may be less serious in younger patients rather than in 
older individuals.45
Using an arbitrary age cut-off of 65 years alone to 
identify those vulnerable to medication problems may 
not be appropriate as, although older patients may be 
more susceptible to the effects of PIP than middle-aged 
people, some younger individuals may also be at high 
risk. Given the increasing burden of multimorbidity, with 
high variation within age groups which can be explained 
by disparity in socioeconomic status and other factors,3 
medicines optimisation efforts may be better aligned with 
illness burden and deprivation rather than just chrono-
logical age.46 This is reinforced by the present study 
which found that numbers of medicines and conditions 
were associated with poorer outcomes in this middle-aged 
cohort. Even within this relatively deprived group, those 
with only primary education had higher rates of ED visits 
compared with those with tertiary education.
cOnclusIOns
A large proportion of middle-aged people in this cohort 
had PIP at baseline and this increased after 2 years of 
follow-up. While no evidence of a significant relation-
ship between the PROMPT criteria and the outcomes of 
healthcare use and QoL was found, numbers of comorbid-
ities and medicines were associated with these outcomes 
in this deprived middle-aged cohort. Further research 
should examine the effects of the PROMPT criteria on 
these and other outcomes and the burden of PIP among 
middle-aged people should be considered when imple-
menting strategies to improve medicines use in other 
patient groups.
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